SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001479290-20-000038
Filing Date
2020-02-24
Accepted
2020-02-24 16:08:49
Documents
16
Period of Report
2020-02-24
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K rvncq419er8-k.htm   iXBRL 8-K 49595
2 EXHIBIT 99.1 rvncq419exhibit991.htm EX-99.1 171643
8 rvnclogooct2019a01.jpg GRAPHIC 14927
  Complete submission text file 0001479290-20-000038.txt   400596

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20200224.xsd EX-101.SCH 4604
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20200224_cal.xml EX-101.CAL 642
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20200224_def.xml EX-101.DEF 1492
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20200224_lab.xml EX-101.LAB 26142
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20200224_pre.xml EX-101.PRE 13598
15 EXTRACTED XBRL INSTANCE DOCUMENT rvncq419er8-k_htm.xml XML 4450
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 20644368
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences